SHR6390

Phase 3

Phase 3

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

Development History

Oct '26

JHPCYPhase 3$38.2B

SHR6390 Phase 3 Est. Readout

SHR6390• Hormone Receptor Positive,Human Epidermal Receptor 2 Negative, Node-positive, High Risk, Early Stage，Female Breast Cancer5,274

Oct 2026~Estimated

00%

Competitive Landscape

0 competitors in Hormone Receptor Positive,Human Epidermal Receptor 2 Negative, Node-positive, High Risk, Early Stage，Female Breast Cancer

Drug Information

Target Indication

Hormone Receptor Positive,Human Epidermal Receptor 2 Negative, Node-positive, High Risk, Early Stage，Female Breast Cancer

Clinical Trial

Last updated: 2/15/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Drug Science

Mechanism of action & safety profile

Developer

JHPCY

Jiangsu Hengrui Pharmaceuticals Co., Ltd./ADR

Related Pipeline

Advanced Solid Tumor

Second-line Treatment for Locally Advanced or Metastatic Pancreatic Cancer After Treatment Failure With Gemcitabine-based Therapy

KNEE OSTEOARTHRITIS

Neuromuscular Blockade

Neuromuscular Blockade

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts